Your browser doesn't support javascript.
loading
Approaches to Quality Risk Management When Using Single-Use Systems in the Manufacture of Biologics.
Ishii-Watabe, Akiko; Hirose, Akihiko; Katori, Noriko; Hashii, Norikata; Arai, Susumu; Awatsu, Hirotoshi; Eiza, Akira; Hara, Yoshiaki; Hattori, Hideshi; Inoue, Tomomi; Isono, Tetsuya; Iwakura, Masahiro; Kajihara, Daisuke; Kasahara, Nobuo; Matsuda, Hiroyuki; Murakami, Sei; Nakagawa, Taishiro; Okumura, Takehiro; Omasa, Takeshi; Takuma, Shinya; Terashima, Iyo; Tsukahara, Masayoshi; Tsutsui, Maiko; Yano, Takahiro; Kawasaki, Nana.
Afiliação
  • Ishii-Watabe A; National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan. watabe@nihs.go.jp.
  • Hirose A; National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan.
  • Katori N; National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan.
  • Hashii N; National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo, 158-8501, Japan.
  • Arai S; Sumitomo Bakelite Co., Ltd., 1-5, Murotani 1-Chome, Nishi-ku, Kobe, 651-2241, Japan.
  • Awatsu H; Nihon Pall Ltd., 6-5-1, Nishishinjuku, Shinjuku-ku, Tokyo, 163-1325, Japan.
  • Eiza A; Sekisui Seikei, Ltd., 2-1-9 Dojimahama, Kita-ku, Osaka, 530-0004, Japan.
  • Hara Y; Sartorius Stedim Japan, 1-8-11 Kitashinagawa Shinagawa-ku, Tokyo, 140-0001, Japan.
  • Hattori H; Dai Nippon Printing Co., Ltd., 1-1-1, Ichigaya Kagacho, Shinjuku-ku, Tokyo, 162-8001, Japan.
  • Inoue T; MSD K.K., 2-3-7 Hiranomachi, Chuo-ku, Osaka, 541-0046, Japan.
  • Isono T; Chugai Pharmaceutical Co., Ltd., 5-1 Ukima 5-Chome Kita-ku, Tokyo, 115-8543, Japan.
  • Iwakura M; Manufacturing Technology Association of Biologics, 2-1-10 Shinkawa, Chuo-ku, Tokyo, 104-0033, Japan.
  • Kajihara D; GE Healthcare Japan Corporation, Sanken Bldg., 3-25-1 Hyakuninchio, Shinjuku-ku, Tokyo, 169-0073, Japan.
  • Kasahara N; Astellas Pharma Tech Co., Ltd., 160-2 Akahama, Takahagi-shi, Ibaraki, 318-0001, Japan.
  • Matsuda H; Fujimori Kogyo Co., Ltd, 1-23-7 Nishi-Shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
  • Murakami S; Hitachi, Ltd., 4-5-2 Higashi-Ikebukuro, Toshima-ku, Tokyo, 170-8466, Japan.
  • Nakagawa T; Kyowa Hakko Kirin Co., Ltd., 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan.
  • Okumura T; Takeda Pharmaceutical Co., Ltd., 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka, 532-8686, Japan.
  • Omasa T; Osaka University, U1E801, 2-1 Yamadaoka, Suita-shi, Osaka, 565-0871, Japan.
  • Takuma S; Chugai Pharmaceutical Co., Ltd., 5-1 Ukima 5-Chome Kita-ku, Tokyo, 115-8543, Japan.
  • Terashima I; Merck Millipore, 1-8-1 Shimomeguro, Meguro-ku, Tokyo, 153-8927, Japan.
  • Tsukahara M; Kyowa Hakko Kirin Co., Ltd., 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan.
  • Tsutsui M; Sumitomo Dainippon Pharma Co., Ltd., 1-3-45 Kurakakiuchi, Ibaraki-shi, Osaka, 567-0878, Japan.
  • Yano T; Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka-shi, Kanagawa, 254-0014, Japan.
  • Kawasaki N; Yokohama City University, 1-7-29 Suehirocho, Tsurumi-ku, Yokohama-shi, Kanagawa, 230-0045, Japan.
AAPS PharmSciTech ; 16(5): 993-1001, 2015 Oct.
Article em En | MEDLINE | ID: mdl-26288941
Biologics manufacturing technology has made great progress in the last decade. One of the most promising new technologies is the single-use system, which has improved the efficiency of biologics manufacturing processes. To ensure safety of biologics when employing such single-use systems in the manufacturing process, various issues need to be considered including possible extractables/leachables and particles arising from the components used in single-use systems. Japanese pharmaceutical manufacturers, together with single-use suppliers, members of the academia and regulatory authorities have discussed the risks of using single-use systems and established control strategies for the quality assurance of biologics. In this study, we describe approaches for quality risk management when employing single-use systems in the manufacturing of biologics. We consider the potential impact of impurities related to single-use components on drug safety and the potential impact of the single-use system on other critical quality attributes as well as the stable supply of biologics. We also suggest a risk-mitigating strategy combining multiple control methods which includes the selection of appropriate single-use components, their inspections upon receipt and before releasing for use and qualification of single-use systems. Communication between suppliers of single-use systems and the users, as well as change controls in the facilities both of suppliers and users, are also important in risk-mitigating strategies. Implementing these control strategies can mitigate the risks attributed to the use of single-use systems. This study will be useful in promoting the development of biologics as well as in ensuring their safety, quality and stable supply.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Gestão de Riscos / Produtos Biológicos / Contaminação de Medicamentos / Tecnologia Farmacêutica / Equipamentos Descartáveis / Indústria Farmacêutica Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Limite: Humans Idioma: En Revista: AAPS PharmSciTech Assunto da revista: FARMACOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Japão País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Gestão de Riscos / Produtos Biológicos / Contaminação de Medicamentos / Tecnologia Farmacêutica / Equipamentos Descartáveis / Indústria Farmacêutica Tipo de estudo: Etiology_studies / Guideline / Risk_factors_studies Limite: Humans Idioma: En Revista: AAPS PharmSciTech Assunto da revista: FARMACOLOGIA Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Japão País de publicação: Estados Unidos